GUBRA Gubra A/S

CPH · DK · Healthcare · Biotechnology · gubra.dk
38.38USD261.00 DKK · CPH-2.25%Mkt Cap: 644.71M USDP/E: —

Gubra A/S, a disease-agnostic techbio company, focuses on the peptide-based drug discovery and preclinical contract research services in Europe, North America, and internationally. It operates through three segments: Pre…

Institutional holders10 on file

Key Statistics

Company
Market Cap644.71M USD
Enterprise Value539.80M USD
Revenue (TTM)39.86M USD
Gross Profit376.01M USD
Net Income (TTM)248.62M USD
Revenue/Share2.44 USD
Last Price38.38 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees330
CountryDK
SectorHealthcare
IndustryBiotechnology
ISINDK0062266474
Valuation
P/E (Trailing)—
P/E (Forward)-14.98
PEG—
EV/EBITDA-19.15
EV/Revenue13.54
P/S16.18
P/B4.19
EPS (TTM)-1.63 USD
EPS (Forward)-2.62 USD
52W Range
38.830% of range81.99
52W High81.99 USD
52W Low38.83 USD
Profitability
Gross Margin96.96%
Oper. Margin-73.07%
EBITDA Margin-70.71%
Profit Margin64.11%
ROE147.53%
ROA128.09%
ROIC990.01%
ROCE174.13%
Growth
Revenue Growth-94.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF251.83M USD
CapEx (TTM)2.82M USD
FCF Margin-661.76%
FCF Yield-40.91%
Net Debt-105.10M USD
Net Debt/EBITDA3.73
Net Debt/FCF—
Balance Sheet
Debt/Equity0.09
Current Ratio11.42
Quick Ratio10.74
Book Value/Sh9.36 USD
Cash/Share8.07 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div DateJun 30, 2025
Pay Date—
Analyst Consensus
Rating1.7 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)75.74 USD
Upside (mean)+97.3%
Target Range65.44 USD – 88.24 USD
65.44+97.3% to mean88.24
# Analysts3
Ownership
Shares Out.16.42M
Float6.81M
Insiders58.23%
Institutions12.99%
Technical
SMA 5043.88 (-12.5%)
SMA 20050.21 (-23.5%)
Beta0.48
S&P 52W Chg12.00%
Avg Vol (30d)58.60K
Avg Vol (10d)84.92K
Technical Indicators
RSI (14)35.3
MACD-5.4251
MACD Signal-2.5839
MACD Hist.-2.8412
BB Upper47.33 USD
BB Middle43.52 USD
BB Lower39.71 USD
BB Width17.52%
ATR (14)2.178 USD
Vol Ratio (20d)0.72x

About Gubra (CPH: GUBRA)

›

Gubra (CPH: GUBRA) is listed on Nasdaq Copenhagen, where its shares trade in DKK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 330 employees.

The shares were at 261.00 DKK on 20 November 2026, down 30.9% over 52 weeks. Its 52-week range is 264.00 DKK to 557.50 DKK, and it trades at the bottom of that range.

Its market capitalisation is 4.38B DKK.

Gubra reports return on equity of 147.5%, an operating margin of -73.1% and revenue down 94.9% year over year.

It holds more cash than debt, a net cash position of 714.64M DKK. Its Piotroski F-score is 9 out of 9, a strong reading of its financial health. 3 analysts cover the stock, with an average rating of Buy; their mean price target of 515.00 DKK is 97.3% above the current price. The next earnings report is expected on 3 March 2027.